Anti-H can trigger apoptosis and down-regulate FUT1 expression in erythroid differentiated K562 cells without complement mediation

Transplant Immunology

Volumn 27, Issue 4, 2012, Pages 151-156

  Zhou, Huayou ^a   Yu, Yantao ^b   Li, Hui ^a   Shi, Wen ^a   Yang, Hecai ^a   Liu, Chixiang ^a   Wang, Shuhong ^a   Yu, Mingming ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b Guangdong Province   (China)

Author keywords

ABH antigens; Anti H; Apoptosis; Down regulation; Erythroid differentiated K562 cells; FUT1 gene

Indexed keywords

ALLOANTIGEN; BLOOD GROUP ABH ANTIGEN; BLOOD GROUP ANTIGEN; BLOOD GROUP H ANTIGEN; COMPLEMENT; FUCOSYLTRANSFERASE; HEMIN; MESSENGER RNA;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD GROUP ABO SYSTEM; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ERYTHROID CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURE RED CELL ANEMIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ABO BLOOD-GROUP SYSTEM; APOPTOSIS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPLEMENT SYSTEM PROTEINS; DOWN-REGULATION; ERYTHROID CELLS; FUCOSYLTRANSFERASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOANTIBODIES; K562 CELLS; RNA, MESSENGER; TRANSPLANTATION IMMUNOLOGY;

EID: 84869871906     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2012.10.001     Document Type: Article

References (29)

1. Stussi G., Halter J., Schanz U., Seebach J.D. ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation. Transfus Apher Sci 2006, 35(1):59-69.
2. Klumpp T.R. Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant 1991, 8(3):159-170.
3. Seebach J.D., Stussi G., Passweg J.R., Loberiza F.R., Gajewski J.L., Keating A., et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005, 11(12):1006-1013.
4. LaRoche V., Eastlund D.T., McCullough J. Review: immunohematologic aspects of allogeneic hematopoietic progenitor cell transplantation. Immunohematology 2004, 20(4):217-225.
5. Cozzi E., Bosio E., Seveso M., Vadori M., Ancona E. Xenotransplantation-current status and future perspectives. Br Med Bull 2006, 75-76:99-114.
6. Koch C.A., Jordan C.E., Platt J.L. Complement-dependent control of teratoma formation by embryonic stem cells. J Immunol 2006, 177(7):4803-4809.
7. Dean A., Erard F., Schneider A.P., Schechter A.N. Induction of hemoglobin accumulation in human K562 cells by hemin is reversible. Science 1981, 212(4493):459-461.
8. Nyoung M.N., Trentesaux C., Aries A., Carpentier Y., Jardillier J.C., Gorisse M.C., et al. Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells. Anticancer Res 1994, 14(3A):1203-1208.
9. Bookout A.L, Cummins C.L., Kramer M.F., Pesola J.M., Mangelsdorf D.J. High-Throughput Real-Time Quantitative Reverse Transcription PCR. Current Protocols in Molecular Biology 2006, 15.8.1-15.8.28. Wiley & Sons, Inc, New York. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.).
10. Takahashi K. A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 2005, 19(Suppl. 14):76-85.
11. Crew R.J., Ratner L.E. ABO-incompatible kidney transplantation: current practice and the decade ahead. Curr Opin Organ Transplant 2010, 15(4):526-530.
12. Lee J.H., Lee K.H., Kim S., Lee J.S., Kim S.H., Kwon S.W., et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000, 25(2):179-184.
13. Takahashi K. Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation. Clin Exp Nephrol 2007, 11(2):128-141.
14. Toki D., Ishida H., Setoguchi K., Shimizu T., Omoto K., Shirakawa H., et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009, 9(3):567-577.
15. Gloor J.M., Lager D.J., Fidler M.E., Grande J.P., Moore S.B., Winters J.L., et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005, 80(11):1572-1577.
16. Tobian A.A., Shirey R.S., Montgomery R.A., Cai W., Haas M., Ness P.M., et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010, 10(5):1247-1253.
17. Kobayashi T., Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 2006, 13(2):136-140.
18. Kumlien G., Wilpert J., Säfwenberg J., Tydén G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation 2007, 84(12 Suppl.):S17-S19.
19. Krishnan N.S., Fleetwood P., Higgins R.M., Hathaway M., Zehnder D., Mitchell D., et al. Application of flow cytometry to monitor antibody levels in ABO incompatible kidney transplantation. Transplantation 2008, 86(3):474-477.
20. Yung G.P., Valli P.V., Starke A., Mueller R.J., Fehr T., Cesar-Ozpamir M., et al. Flow cytometric measurement of ABO antibodies in ABO-incompatible living donor kidney transplantation. Transplantation 2007, 84(12 Suppl.):S20-S23.
21. Takahashi K. Accommodation in ABO-incompatible kidney transplantation: why do kidney grafts survive?. Transplant Proc 2004, 36(2 Suppl.):193S-196S.
22. Lynch R.J., Platt J.L. Accommodation in organ transplantation. Curr Opin Organ Transplant 2008, 13(2):165-170.
23. Szulman A.E. The histological distribution of blood group substances A and B in man. J Exp Med 1960, 111:785-800.
24. Hogman C. The principle of mixed agglutination applied to tissue culture systems; a method for study of cell-bound blood-group antigens. Vox Sang 1959, 4(1):12-20.
25. Breimer M.E., Mölne J., Nordén G., Rydberg L., Thiel G., Svalander C.T. Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status. Transplantation 2006, 82(4):479-485.
26. Takahashi K. ABO-incompatible kidney transplantation 2001, 1. Elsevier Science, Amsterdam.
27. Tasaki M., Nakajima T., Imai N., Nakagawa Y., Saito K., Takahashi K., et al. Detection of allogeneic blood group A and B enzyme activities in patients with ABO incompatible kidney transplantation. Glycobiology 2010, 20(10):1251-1258.
28. Tanabe T., Ishida H., Horita S., Yamaguchi Y., Toma H., Tanabe K. Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transpl Immunol 2011, 25(1):1-6.
29. Kobayashi T., Liu D., Ogawa H., Miwa Y., Nagasaka T., Maruyama S., et al. Removal of blood group A/B antigen in organs by ex vivo and in vivo administration of endo-beta-galactosidase (ABase) for ABO-incompatible transplantation. Transpl Immunol 2009, 20(3):132-138.